Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 125, Issue 7, Pages 2551-2557Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI80575
Keywords
-
Categories
Funding
- American Heart Association [12POST12050363, 14GNT18970018]
- NIH [R01 HL123968, NIH R24 HL117756]
- California Institute for Regenerative Medicine [IT1-06596, TR3-05556, DR2A-05394]
Ask authors/readers for more resources
Human pluripotent stem cells are known to have the capacity to renew indefinitely, being intrinsically able to differentiate into many different cell types. These characteristics have generated tremendous enthusiasm about the potential applications of these cells in regenerative medicine. However, major challenges remain with the development and testing of novel experimental stem cell therapeutics in the field. In this Review, we focus on the nature of the preclinical challenges and discuss potential solutions that could help overcome them. Furthermore, we discuss the use of allogeneic versus autologous stem cell products, including a review of their respective advantages and disadvantages, major clinical requirements, quality standards, time lines, and costs of clinical grade development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available